» Articles » PMID: 20186654

Inhibition of the Ubiquitin-proteasome System by Natural Products for Cancer Therapy

Overview
Journal Planta Med
Specialty Biology
Date 2010 Feb 27
PMID 20186654
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The ubiquitin-proteasome system plays a critical role in selective protein degradation and regulates almost all cellular events such as cell cycle progression, signal transduction, cell death, immune responses, metabolism, protein quality control, development, and neuronal function. The recent approval of bortezomib, a synthetic proteasome inhibitor, for the treatment of relapsed multiple myeloma has opened the way to the discovery of drugs targeting the proteasome and ubiquitinating and deubiquitinating enzymes as well as the delivery system. To date, various synthetic and natural products have been reported to inhibit the components of the ubiquitin-proteasome system. Here, we review natural products targeting the ubiquitin-proteasome system as well as synthetic compounds with potent inhibitory effects.

Citing Articles

Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.

Ambrosio F, Costa G, Gallo Cantafio M, Torcasio R, Trapasso F, Alcaro S Molecules. 2023; 28(3).

PMID: 36771100 PMC: 9919276. DOI: 10.3390/molecules28031438.


Identification of a lysine 4-hydroxylase from the glidobactin biosynthesis and evaluation of its biocatalytic potential.

Amatuni A, Renata H Org Biomol Chem. 2018; 17(7):1736-1739.

PMID: 30320324 PMC: 6374188. DOI: 10.1039/c8ob02054j.


Copy number variation of E3 ubiquitin ligase genes in peripheral blood leukocyte and colorectal cancer.

Bi H, Tian T, Zhu L, Zhou H, Hu H, Liu Y Sci Rep. 2016; 6:29869.

PMID: 27417709 PMC: 4945909. DOI: 10.1038/srep29869.


Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.

Czerwinski A, Basava C, Dauter M, Dauter Z Acta Crystallogr E Crystallogr Commun. 2015; 71(Pt 3):254-7.

PMID: 25844180 PMC: 4350719. DOI: 10.1107/S2056989015002091.


Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Dou Q, Zonder J Curr Cancer Drug Targets. 2014; 14(6):517-36.

PMID: 25092212 PMC: 4279864. DOI: 10.2174/1568009614666140804154511.